Aratana Therapeutics (NASDAQ:PETX)‘s stock had its “outperform” rating reissued by equities researchers at Credit Suisse Group in a report issued on Friday, March 16th. They currently have a $8.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $9.00. Credit Suisse Group’s price objective suggests a potential upside of 62.27% from the stock’s current price.
A number of other research analysts have also recently commented on PETX. Zacks Investment Research upgraded shares of Aratana Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, March 7th. Jefferies Group set a $9.00 price target on Aratana Therapeutics and gave the stock a “buy” rating in a research note on Thursday, November 16th. ValuEngine lowered Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st. CL King upgraded Aratana Therapeutics from a “neutral” rating to a “buy” rating and set a $8.00 price objective for the company in a report on Monday, March 12th. They noted that the move was a valuation call. Finally, HC Wainwright set a $10.00 price objective on Aratana Therapeutics and gave the stock a “buy” rating in a report on Thursday, December 21st. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $8.68.
PETX traded down $0.16 during mid-day trading on Friday, reaching $4.93. 581,329 shares of the stock were exchanged, compared to its average volume of 784,027. The company has a debt-to-equity ratio of 0.24, a current ratio of 2.40 and a quick ratio of 2.02. The company has a market capitalization of $226.06, a price-to-earnings ratio of -5.08 and a beta of 2.91. Aratana Therapeutics has a 1 year low of $3.67 and a 1 year high of $7.67.
Aratana Therapeutics (NASDAQ:PETX) last released its quarterly earnings data on Tuesday, March 13th. The biopharmaceutical company reported ($0.19) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.04. Aratana Therapeutics had a negative net margin of 185.78% and a negative return on equity of 45.15%. The business had revenue of $10.46 million for the quarter, compared to the consensus estimate of $5.72 million. equities analysts anticipate that Aratana Therapeutics will post -0.61 EPS for the current year.
In related news, insider Craig A. Tooman sold 30,000 shares of the business’s stock in a transaction that occurred on Thursday, January 11th. The stock was sold at an average price of $5.27, for a total value of $158,100.00. Following the transaction, the insider now directly owns 75,024 shares of the company’s stock, valued at approximately $395,376.48. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Peter Steven St sold 19,367 shares of the business’s stock in a transaction that occurred on Tuesday, January 30th. The stock was sold at an average price of $4.77, for a total value of $92,380.59. Following the completion of the transaction, the chief executive officer now directly owns 672,259 shares in the company, valued at $3,206,675.43. The disclosure for this sale can be found here. 5.20% of the stock is owned by insiders.
Institutional investors and hedge funds have recently bought and sold shares of the stock. Wells Fargo & Company MN boosted its holdings in Aratana Therapeutics by 20.8% during the 3rd quarter. Wells Fargo & Company MN now owns 367,365 shares of the biopharmaceutical company’s stock valued at $2,252,000 after acquiring an additional 63,377 shares during the period. State Street Corp lifted its holdings in shares of Aratana Therapeutics by 10.2% in the 2nd quarter. State Street Corp now owns 597,180 shares of the biopharmaceutical company’s stock worth $4,317,000 after buying an additional 55,480 shares during the period. Alyeska Investment Group L.P. lifted its holdings in shares of Aratana Therapeutics by 10.5% in the 3rd quarter. Alyeska Investment Group L.P. now owns 964,116 shares of the biopharmaceutical company’s stock worth $5,910,000 after buying an additional 91,763 shares during the period. General American Investors Co. Inc. lifted its holdings in shares of Aratana Therapeutics by 28.9% in the 4th quarter. General American Investors Co. Inc. now owns 1,117,923 shares of the biopharmaceutical company’s stock worth $5,880,000 after buying an additional 250,323 shares during the period. Finally, Northern Trust Corp lifted its holdings in shares of Aratana Therapeutics by 10.5% in the 2nd quarter. Northern Trust Corp now owns 463,984 shares of the biopharmaceutical company’s stock worth $3,355,000 after buying an additional 43,967 shares during the period. Institutional investors own 66.65% of the company’s stock.
WARNING: “Aratana Therapeutics (NASDAQ:PETX) Stock Rating Reaffirmed by Credit Suisse Group” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/09/aratana-therapeutics-petx-receives-outperform-rating-from-credit-suisse-group.html.
Aratana Therapeutics Company Profile
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.